title: Intensive Atorvastatin Therapy Attenuates the Inflammatory Responses in Monocytes of Patients with Unstable Angina Undergoing Percutaneous Coronary Intervention via Peroxisome Proliferator-Activated Receptor γ Activation.
abstract: Periprocedural myocardial injury is a prognostically important complication of percutaneous coronary intervention (PCI). However, it still remains unclear whether and how intensive atorvastatin therapy attenuates the unfavorable inflammatory responses of monocytes associated with PCI. The aim of the study was to investigate the impact of intensive atorvastatin therapy on inflammatory responses of monocytes in Chinese patients with unstable angina who received PCI in order to explore the potential anti-inflammatory mechanism. Ninety-six patients with unstable angina were randomly assigned to atorvastatin 80 mg (intensive) or atorvastatin 20 mg (conventional) treatment at a 1:1 ratio. Creatine kinase MB (CK-MB), cTnI, hs-CRP, and IL-6 were assessed, and circulating CD14(+) monocytes were simultaneously obtained using CD14 MicroBeads 2 h before and 24 h after PCI. Plasma levels of CK-MB, cTnI, hs-CRP, and IL-6 were higher in the conventional dose group versus those in the intensive dose group following PCI. Furthermore, intensive atorvastatin treatment markedly reduced the expressions and responses of Toll-like receptor 2 (TLR2), TLR4, and CCR2 of CD14(+) monocytes versus the conventional dose group and significantly increased the activated peroxisome-proliferator-activated receptor (PPAR) γ in the CD14(+) monocytes post-PCI. Notably, the changes in responses of TLR2, TLR4, and CCR2 of CD14(+) monocytes between the two groups were all reversed by PPARγ antagonist and augmented by PPARγ agonist. In conclusion, a single high (80 mg) loading dose of atorvastatin reduced the inflammatory response in Chinese patients with unstable angina following PCI. The anti-inflammatory role of intensive atorvastatin was possibly due to attenuation of inflammatory response in monocytes via PPARγ activation.
authors.affiliation: Department of Geriatrics, Tangshan Gongren Hospital, Tangshan, Hebei, 063000, People's Republic of China.
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
authors.forename: Changqing
authors.initials: C
authors.lastname: Liu
authors.forename: Linxia
authors.initials: L
authors.lastname: Zhang
authors.forename: Yanhui
authors.initials: Y
authors.lastname: Liu
authors.forename: Aihua
authors.initials: A
authors.lastname: Guo
authors.forename: Huiwu
authors.initials: H
authors.lastname: Shi
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Liu
authors.forename: Ying
authors.initials: Y
authors.lastname: Cheng
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D000069059:Atorvastatin / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000517:prevention & control; D018836:Inflammation Mediators / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D047495:PPAR gamma / Q000097:blood*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*
chemical_list: D018836:Inflammation Mediators; D047495:PPAR gamma; D000069059:Atorvastatin